top of page
Shalini Andersson-2.jpg

Dr Shalini Andersson

Astra Zeneca AB, Discovery Sciences, Gothenburg, Sweden



Shalini Andersson is Chief Scientist and Head of Oligonucleotide Discovery in BioPharmaceuticals R&D at AstraZeneca, Göteborg, Sweden.


Shalini Andersson is currently Chief Scientist and Head of Oligonucleotide Discovery in BioPharmaceuticals R&D. Shalini has also the strategic responsibility for explorative activities and build of capabilities in the new therapeutic modalities area.

Shalini has broad experience in Pharmaceutical research as well as of strategic and management roles and drives several collaborations with external partners and academic groups across the globe.

Prior to this role, Shalini held several leadership roles within Cardiovascular, renal and metabolism.

Shalini is also leading the Targeted Drug Delivery platform projects and is involved in collaborations with Ionis Pharma, Silence Therapeutics and OligoNova within the RNA field. Shalini is member of the board of the Oligonucleotide Therapeutics Soc. as well as of the scientific advisory group for NATA (UK) and member of the steering group for OligoNova.

Shalini received her PhD in 1989 at the University of Linköping, Sweden and has held various research and teaching positions at the University of Linköping prior to moving to industry. She is the author or co-author of over 45 peer reviewed articles, 2 book chapters and 4 patents.

Host Laboratory

We have state-of-the-art purpose-built laboratories with facilities to develop small molecules and nucleotide therapeutics by means of molecular and chemical biology approaches. This includes a wide range of facilities from target identification, compound design and selection; compound synthesis, purification and analysis; compound library generation; high-throughput assays for identifying active compounds; cell and animal model-based preclinical studies; bioinformatics and biomarker discovery; drug delivery as well as clinical trials of drug compounds (small molecules and oligonucleotides). Expertise in commercialisation (invention-to-market process) and IP protection.




+46 708 46 7335

Head of New Modalities, Innovative Medicines Biotech Unit
Astra Zeneca
Cardiovascular, Renal and Metabolism
Pepparedsleden 1
43150 Molndal

bottom of page